Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors
- 31 August 2020
- journal article
- research article
- Published by Elsevier BV in Pharmacological Research
- Vol. 159, 104940
- https://doi.org/10.1016/j.phrs.2020.104940
Abstract
No abstract availableFunding Information
- Spanish Ministerio de Economia y Competitividad (#BFU2015-64405-R, SAF2017-84117-R, #RTI2018-094204)
- Alzheimer’s Association (AARFD-17-503612)
This publication has 62 references indexed in Scilit:
- New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2British Journal of Pharmacology, 2013
- N-Arachidonyl Glycine Does Not Activate G Protein–Coupled Receptor 18 Signaling via Canonical PathwaysMolecular Pharmacology, 2012
- Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in BrainOnline Journal of Public Health Informatics, 2012
- Quantifying Ligand Bias at Seven-Transmembrane ReceptorsMolecular Pharmacology, 2011
- Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex ofMacaca fascicularisJournal of Psychopharmacology, 2010
- N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptorBMC Neuroscience, 2010
- Building a new conceptual framework for receptor heteromersNature Chemical Biology, 2009
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Identification of a New Chemotype inCannabis sativa: Cannabigerol - Dominant Plants, Biogenetic and Agronomic ProspectsPlanta Medica, 1987
- Biological Activity of Cannabichromene, its Homologs and IsomersThe Journal of Clinical Pharmacology, 1981